Assessing risk and managingMycobacterium tuberculosisinfection and disease in patients due to start anti-TNFα treatment

    loading  Checking for direct PDF access through Ovid


This short paper describes the rationale being applied in the United Kingdom to the problem of treating latent TB infection in persons requiring anti-TNF-alpha treatment. This will largely have to be done by an individual risk/benefit analysis based on the risks of developing disease from national epidemiology compared with the risks of significant hepatotoxicity from treatment of latent infection.

    loading  Loading Related Articles